CD34, CD4, and CD8 cell doses do not influence engraftment, graft-versus-host disease, or survival following myeloablative human leukocyte antigen-identical peripheral blood allografting for hematologic malignancies-Reference-Cited by-同舟云学术

CD34, CD4, and CD8 cell doses do not influence engraftment, graft-versus-host disease, or survival following myeloablative human leukocyte antigen-identical peripheral blood allografting for hematologic malignancies

Published:2005-03 Issue:3 Volume:33 Page:279-285
ISSN:0301-472X
Container-title:Experimental Hematology
language:en
Short-container-title:Experimental Hematology

Author:

Cao Thai M.,Wong Ruby M.,Sheehan Kevin,Laport Ginna G.,Stockerl-Goldstein Keith E.,Johnston Laura J.,Shizuru Judith A.,Negrin Robert S.,Lowsky Robert

Publisher

Elsevier BV

Subject

Cancer Research,Cell Biology,Genetics,Hematology,Molecular Biology

Reference35 articles.

1. Therapeutic relevance of CD34 cell dose in blood cell transplantation for cancer therapy;Siena;J Clin Oncol,2000

2. HLA-identical stem cell transplantation: is there an optimal CD34 cell dose?;Heimfeld;Bone Marrow Transplant,2003

3. Chronic graft-versus-host disease after allogeneic blood stem cell transplantation;Przepiorka;Blood,2001

4. Influence of transplanted dose of CD56+ cells on development of graft-versus-host disease in patients receiving G-CSF-mobilized peripheral blood progenitor cells from HLA-identical sibling donors;Yamasaki;Bone Marrow Transplant,2003

5. A randomized multicenter comparison of CD34(+)-selected progenitor cells from blood vs from bone marrow in recipients of HLA-identical allogeneic transplants for hematological malignancies;Cornelissen;Exp Hematol,2003

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Graft CD8 T‐cell‐based risk system predicts survival in antithymocyte globulin‐based myeloablative haploidentical peripheral blood stem cell transplantation;Clinical & Translational Immunology;2024-01

2. Day 4 collection of granulocyte colony-stimulating factor-mobilized HLA-matched sibling donor peripheral blood allografts demonstrates no long-term increase in chronic graft-versus-host disease or relapse rates;Cytotherapy;2023-04

3. Adverse impact of a high CD4/CD8 ratio in the allograft may be overcome by methotrexate‐ but not mycophenolate‐ or post‐transplant cyclophosphamide‐based graft versus host disease prophylaxis;European Journal of Haematology;2023-03-28

4. Effect of CD34+ Cell Dose on the Outcomes of Allogeneic Stem Cell Transplantation with Post-Transplantation Cyclophosphamide;Transplantation and Cellular Therapy;2023-03

5. Impact of Lymphocyte Subsets of Grafts on the Outcome of Haploidentical Peripheral Blood Stem Cell Transplantation;Cell Transplantation;2023-01